{"denoms":[{"counts":[{"groupId":"BG000","value":"86"}],"units":"Participants"}],"groups":[{"description":"Zanubrutinib (160 mg) administered BID until Zanubrutinib (160 milligrams \\[mg\\]) administered orally twice daily (BID) until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow up, or study termination by sponsor, which comes first.","id":"BG000","title":"Zanubrutinib"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.18","value":"59.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"64"}]}],"title":"< 65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"22"}]}],"title":"≥ 65 years"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"67"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"86"}]}],"title":"Chinese"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"86"}]}],"title":"China"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"MCL Stage I"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"MCL Stage II"},{"measurements":[{"groupId":"BG000","value":"14"}],"title":"MCL Stage III"},{"measurements":[{"groupId":"BG000","value":"64"}],"title":"MCL Stage IV"}]}],"description":"Participants' MCL disease stage at consent date, with higher stages indicating more severe MCL.","paramType":"COUNT_OF_PARTICIPANTS","title":"Mantle Cell Lymphoma (MCL) Disease Stage at Study Entry","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"41"}],"title":"Relapsed Disease"},{"measurements":[{"groupId":"BG000","value":"45"}],"title":"Refractory Disease"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Disease Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60"}],"title":"Grade 0"},{"measurements":[{"groupId":"BG000","value":"22"}],"title":"Grade 1"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Grade 2"}]}],"description":"Grade 0 = Fully active, able to carry on all pre-disease performance without restriction; Grade 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, eg, light house work, office work; Grade 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; Lower grades indicate better outcome.","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group Performance Status","unitOfMeasure":"Participants"}],"populationDescription":"Safety Analysis Set: All participants who received any dose of study drug."}